A patient with rheumatoid arthritis developed a reversible, primary cutaneous, large B cell lymphoma during prolonged methotrexate (MTX) treatment. Regression of the skin lesions after discontinuation of the drug suggested a close relationship to MTX. Increased clinical awareness, discontinuation of MTX, and close observation are important in the initial management of this rare lymphoproliferative disorder.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Bloodstream infection in a neonatal intensive care unit: Epidemiology, Antifungal susceptibility and new drug delivered strategies.
J Mycol Med
January 2025
Mycology Laboratory, School of Pharmacy, Midwestern Paraná State University, UNICENTRO, PR, Brazil. Electronic address:
Bloodstream infection in neonates is a complicated disease and presents a major challenge both in diagnosis and in therapeutic intervention. The focus of the present study was to investigate the incidence, the species distribution and the risk factors associated with mortality of bloodstream infections in a neonatal intensive care unit (NICU) and evaluating the antifungal susceptibility of traditional antifungal drugs and three nanoparticle-based drug delivery systems based on nanoparticles. A total of 458 patients were evaluated, and 9.
View Article and Find Full Text PDFA Rare Head and Neck Tumor: Making Simple Things Complicated.
Cureus
December 2024
Pathology, Sir Ganga Ram Hospital, New Delhi, IND.
Primary cutaneous anaplastic large cell lymphoma (ALCL) is a very uncommon type of CD30-positive T-cell lymphoma, and it very rarely affects the forehead. We report the case of a 68-year-old male presenting with an ulcerative lesion on the right forehead, initially suspected as a benign condition. Fine needle aspiration suggested a lymphoproliferative disorder, with biopsy and immunohistochemistry confirming primary cutaneous ALCL (CD30-positive, anaplastic lymphoma kinase [ALK]-negative).
View Article and Find Full Text PDFDevelopment and Evaluation of the Dermatomyositis Outcomes for Muscle and Skin as an Outcome Measure in Dermatomyositis Clinical Trials.
JID Innov
March 2025
Corporal Micheal J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
The Total Improvement Score (TIS), which is used as the primary efficacy measure in dermatomyositis (DM) clinical trials, lacks a skin-specific measure. However, skin is a defining feature of DM. In this study, data were analyzed from the phase 3 trial of lenabasum in DM.
View Article and Find Full Text PDFSignificance of HLA-B*15 in three pemphigus patients with rituximab-triggered severe cutaneous drug reactions.
Postepy Dermatol Alergol
December 2024
Department of Dermatology and Venerology, First Affiliated Hospital of Kunming Medical University, Kunming, China.
Introduction: Rituximab, a CD20 inhibitor, has swiftly become the primary treatment for pemphigus patients.
Aim: We present 3 cases of pemphigus patients who had undergone rituximab treatment.
Material And Methods: After the second intravenous administration of rituximab, the primary rash developed into severe cutaneous drug reactions.
Insulin-Induced Lipohypertrophy Treated With Liposuction: A Review of Case Reports.
Plast Surg (Oakv)
February 2025
Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Lipohypertrophy is the most reported cutaneous complication of insulin injection. In cases refractory to conservative management, liposuction has been proposed as a treatment. This review aims to evaluate the use of liposuction for the treatment of insulin-induced lipohypertrophy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!